Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
- Department for International Development
- Uganda and Zimbabwe
- Document Type:
- Journal Article
- Grosskurth, H., Stöhr, W., Walker, A.S., Kityo, C., Mugyenyi, P. Munderi, P., Hakim, J., Gibb, D.M., Ssali, F., Reid, A., Darbyshire, J.H., Gilks, C.F, and DART Trial Team
OBJECTIVE: To describe the prevalence, incidence and predictors of severe anaemia in previously untreated symptomatic HIV-infected adults with CD4+ T-cells 3 initiating zidovudine-containing regimens in Africa. DESIGN: DART is a randomized trial comparing two strategies for HIV/AIDS management in Uganda and Zimbabwe. Methods: We analysed the occurrence of anaemia at weeks 4 and 12, and then every 12 weeks. We also evaluated sex, age, WHO stage, body mass index (BMI), baseline laboratory measurements and first regimen as predictors of developing grade 4 anaemia (3 and median baseline haemoglobin=11.4 g/dl) had a median 72 weeks follow-up. Prevalence of grade 4 anaemia was 0.7%, 2.0%, 0.5% and
Ssali, F.; Stöhr, W.; Munderi, P.; Reid, A.; Walker, A.S.; Gibb, D.M.; Mugyenyi, P.; Kityo, C.; Grosskurth, H.; Hakim, J.; Darbyshire, J.H.; Gilks, C.F; DART Trial Team. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antiviral Therapy (2006) 11 (6) 741-749.